How Multi-Gene Panel Testing Works
A single sample, read across dozens of hereditary-cancer genes at once. Here is what a panel is, how next-generation sequencing makes it possible, and the trade-offs that come with looking at more genes — including the uncertain findings the PROMPT Study was built to track.
Panel Testing Explained
From one gene to many in a single test
A multi-gene panel is a single laboratory test that examines a defined list of genes in parallel — anywhere from a handful to more than a hundred. Each gene on the list is one where inherited variants are known, or suspected, to raise the risk of certain cancers. Rather than ordering one gene at a time and waiting for each result before deciding what to test next, the panel reads them all from the same DNA sample.
For more than two decades, hereditary-cancer testing was sequential: a clinician suspected a syndrome, ordered the one or two genes that fit, and stopped if the result was negative. That approach worked when the suspected gene matched the family history. It missed cases where the inherited risk came from a gene nobody thought to order — which, as panels later revealed, happened more often than expected.
How next-generation sequencing reads many genes at once
Panels are made practical by next-generation sequencing (NGS), a method that reads millions of short DNA fragments simultaneously rather than one stretch at a time. The relevant regions of each targeted gene are first captured or amplified from the sample, then sequenced in massively parallel reactions. Software aligns the resulting reads against a reference genome and flags positions where a person's sequence differs.
Because the same run can cover many genes, the marginal cost of adding another gene to a panel is small. That economics is what shifted hereditary-cancer testing from a one-gene-at-a-time inquiry into a broad, parallel survey. The same shift also explains why panels surface more variants overall — the sequencer is simply reading more places where a difference can appear.
The typical workflow, from order to report
A panel result moves through several deliberate stages. Understanding the sequence helps set expectations for how long it takes and why each step matters.
1. Order and pre-test counseling
A clinician or genetic counselor reviews personal and family history, explains what a panel can and cannot answer, and chooses the gene list. Informed consent covers the possibility of uncertain findings before any sample is taken.
2. Sample collection
DNA is obtained from a blood draw, a saliva sample, or a buccal (cheek) swab. All three yield the germline DNA a hereditary-cancer panel needs; the choice depends on logistics and laboratory preference, not on the quality of the answer.
3. Sequencing and analysis
The laboratory extracts DNA, sequences the targeted genes by NGS, and runs bioinformatic pipelines to call variants. Regions that sequence poorly may be confirmed by a secondary method so no part of a gene is silently missed.
4. Variant classification
Each variant is weighed against population databases, functional studies, and published evidence, then classified — typically as benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. This interpretive step, not the sequencing, is where most of the clinical judgment lives.
5. Report and post-test counseling
Results are returned to the ordering clinician, who reviews them with the patient. Positive, negative, and uncertain results each carry different implications for screening, prevention, and testing of relatives — which is why the conversation matters as much as the report.
Targeted versus comprehensive panels
Not every panel is the same size. A targeted panel includes only the genes most relevant to a specific clinical picture — for example, a focused set tied to one suspected syndrome or one cancer type. A comprehensive panel casts a wider net, covering genes with weaker or less certain links to risk.
The trade-off is direct. A broader panel is more likely to find a clinically actionable variant that a narrow one would have missed — but it is also more likely to return a variant of uncertain significance or a finding in a gene whose risk is not yet well defined. Panel choice is therefore a deliberate decision, made with a clinician, that balances the chance of a useful answer against the chance of an ambiguous one.
Frequently asked questions
Why did panels replace single-gene testing?
Sequential, one-gene-at-a-time testing was slow and could miss inherited risk that lived in a gene the clinician did not think to order. Once next-generation sequencing made it inexpensive to read many genes from a single sample, a panel could answer in one test what previously took several — and could catch risk genes that family history alone would not have pointed to. Panels became the default for most hereditary-cancer evaluations as a result.
What is a variant of uncertain significance?
A variant of uncertain significance (VUS) is a genetic difference that the laboratory cannot confidently classify as harmful or harmless given current evidence. It is not a positive result and is generally not used to guide medical decisions. Many VUS are later reclassified as benign as more data accumulate. Broader panels return more of them simply because they read more genes — one of the central trade-offs of comprehensive testing.
Does a larger panel give a better answer?
Not necessarily. A larger panel improves the chance of detecting an actionable variant, but it also raises the chance of an uncertain or hard-to-interpret finding, and may include genes whose cancer risk is not yet well established. The right size of panel depends on the clinical question, the family history, and what a patient and clinician are prepared to act on — which is why panel selection is a counseled decision rather than a default to the biggest list.
What does the PROMPT Study have to do with panel testing?
The PROMPT Study — the Prospective Registry Of MultiPlex Testing — was created precisely because panels introduced new uncertainty. As multi-gene testing spread, clinicians and patients faced more variants in less-studied genes and more findings of uncertain significance. PROMPT pooled information from patients who underwent panel testing across multiple institutions so that the long-term meaning of those findings could be studied systematically. This page reflects that same evidence-minded view of what panels can and cannot tell you.
Questions about how panel testing works?
We publish plain-language, evidence-based explainers on hereditary cancer genetics, multi-gene panels, and what patient registries reveal about uncertain findings. Reach out if there is a topic you would like us to cover.